Randomized controlled trial reveals that adding nemolizumab to topical therapy reduces pruritus in atopic dermatitis, suggesting a potential targeted treatment for severe itch.
In this 16-week trial, the use of subcutaneous nemolizumab in addition to topical agents for atopic dermatitis resulted in a greater reduction in pruritus than placebo plus topical agents. The incidence of injection-site reactions was greater with nemolizumab than with placebo. Longer and larger trials are necessary to determine whether nemolizumab has a durable effect and is safe for atopic dermatitis. (Funded by Maruho; JapicCTI number, 173740.).
No takes yet. Share an insight, caveat, or question.
Kabashima et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: